Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01881542
Other study ID # 0157-12-EMC
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 2013
Est. completion date August 2023

Study information

Verified date August 2022
Source HaEmek Medical Center, Israel
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background and project rationale: Preeclampsia is a common complication of pregnancy, affecting 6-8% of all pregnancies and constitutes a leading cause of maternal morbidity and mortality. Preeclampsia is liable to endanger the lives of both the gravida and the fetus, particularly if treatment is initiated inappropriately or in an untimely fashion. Diagnosis of preeclampsia is dependent on the finding of proteinuria, determined as being over 300mg of protein in a 24 hours urine sample. However, urine collection spanning 24 hours sometimes constitutes a "bottleneck", extending the time to diagnosis of preeclampsia. Additionally, the collection of urine for 24 hours entails a degree of discomfort, requiring that the woman be in proximity to for collection vessel, and increases the length of her hospital admission. The use of an abbreviated test may permit diagnosis and treatment in a more timely fashion. Similarly, the ability to exclude the diagnosis more rapidly could reduce length of hospital stay and consumption of the health system's limited resources. Further, a shorter test may reduce the discomfort associated with the 24-hour test and thus increase compliance. Previous research has suggested that briefer tests correlate with the traditional 24 hour urine collection, however these studies were based on small study populations. Research Objective: To validate a brief and rapid test for the diagnosis of urinary protein excretion. To assess whether, in women with suspected preeclampsia, a difference exists between protein excretion during the daytime and at night. Methods: Urine collection will be performed on pregnant women admitted for investigation of suspected preeclampsia, with volumes recorded and samples taken at 6, 12 and 24 hour intervals for assessment of urinary protein content. As such, a comparison will be made between the protein excretion after 6 and 12 hours with that over a full 24 hour period; in addition, comparison will be made between daytime and nighttime urinary protein excretion. The results will allow for assessment of whether a shorter test can substitute the full 24 hour collection in the diagnosis of preeclampsia; results of women who are shown to not suffer from preeclampsia will be used to assess whether a short test can rule out the disease. Additionally a urine sample for protein/creatinine ratio will be examined and correlated with results of the different collection periods.


Description:

Literature review and project rationale: Preeclampsia is a common complication of pregnancy, affecting 6-8% of all pregnancies and constitutes a leading cause of maternal morbidity and mortality. Preeclampsia is liable to endanger the lives of both the gravida and the fetus, particularly if treatment is initiated inappropriately or in an untimely fashion. The diagnosis of preeclampsia is based on findings of raised blood pressure (over 140/90mmHg) and the presence of proteinuria. The accepted means of measuring proteinuria is by 24-hour urine collection, with a pathological value defined as 300mg or greater in the 24 hour period. When the proteinuria is greater than 5000mg in 24 hours, the pr-eclampsia is classified as severe and is further endangers the lives of the expectant mother and fetus and often results in early delivery. Diagnosis and assessment of severity of preeclampsia require a timely situation assessment. Urine collection spanning 24 hours sometimes constitutes a "bottleneck", extending the time to diagnosis of preeclampsia. Additionally, the collection of urine for 24 hours entails a degree of discomfort, requiring that the woman be in proximity to for collection vessel, and increases the length of her hospital admission. The use of an abbreviated test may permit diagnosis and treatment in a more timely fashion. Similarly, the ability to exclude the diagnosis more rapidly could reduce length of hospital stay and consumption of the health system's limited resources. Further, a shorter test may reduce the discomfort associated with the 24-hour test and thus increase compliance. Previous research has shown that 8-hour urine collection does indeed produce results paralleling the 24-hour collection, and recent research also demonstrates concordance between 12-hour and 24-hour urine collections. That said, both these studies were based on small sample populations, fewer than 100 women. Another study of women with preeclampsia showed good correlation between the results of urinary protein in samples collected over 12 hours at night and those collected over 12 hours during daytime. Research Assumptions: 1. urine collection for a period of time less than 24 hours will reflect the degree of urinary protein excretion. 2. urine collection for a period of time less than 24 hours will constitute an alternative test for 24-hour urine collection, the accepted diagnostic test today. Research Objective: To validate a brief and rapid test for the diagnosis of urinary protein excretion. To assess whether, in women with suspected preeclampsia, a difference exists between protein excretion during the daytime and at night. Methods: Urine collection is to be performed on every pregnant admitted for investigation of suspected preeclampsia. After 6, 12 and 24 hours samples of the collected urine will be taken for protein concentration assessment. Quantitative urinary protein will be established according to urinary protein concentration and collected urine volume. Results of the tests after 6 and 12 hours will be compared to the final results after 24 hours, that being the test of choice for diagnosis of proteinuria in preeclampsia and thus the test that will determine management (according to department protocol). Women for whom preeclampsia has been ruled out (viz, those who underwent investigation following raised BP but without a finding of proteinuria) will serve to assess the ability of a short urine collection to rule out proteinuria and, as such, preeclampsia. So as to assess whether there is a difference between results of daytime urinary protein excretion and those at night, the urine collection will be performed in two vessels as follows: 1. 8:00am - beginning of urine collection 2. 2:00pm, vessel 1 - recording of collected urine volume, removal of a 10mL sample of urine for protein concentration testing. 3. 8:00pm, vessel 1 - recording of total collected urine volume, removal of a 10mL sample of urine for protein concentration testing. at this point urine collection will be continued in the second vessel 4. 8:00am the following morning, vessel 2 - recording of collected urine volume as of 8:00pm (the previous 12 hours), removal of a 10mL sample of urine for protein concentration testing. 5. contents of the two vessels are mixed, 24 hour urine volume recorded and a 10mL sample taken, this being the sample that will establish the result of the 24 hour urine collection. Additionally a urine sample for protein/creatinine ratio will be examined and correlated with results of the different collection periods.


Recruitment information / eligibility

Status Completed
Enrollment 307
Est. completion date August 2023
Est. primary completion date July 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - pregnant women - age 18-55 years - blood pressure >140mmHg systolic or >90mmHg diastolic Exclusion Criteria: - known renal disease - urinary tract infection - spontaneous labor or need to induce labor within the first 24 hours of admission

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Israel HaEmek Medical Center Afula

Sponsors (1)

Lead Sponsor Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

References & Publications (4)

Adelberg AM, Miller J, Doerzbacher M, Lambers DS. Correlation of quantitative protein measurements in 8-, 12-, and 24-hour urine samples for the diagnosis of preeclampsia. Am J Obstet Gynecol. 2001 Oct;185(4):804-7. doi: 10.1067/mob.2001.117302. — View Citation

Kieler H, Zettergren T, Svensson H, Dickman PW, Larsson A. Assessing urinary albumin excretion in pre-eclamptic women: which sample to use? BJOG. 2003 Jan;110(1):12-7. — View Citation

Shennan AH, Redman C, Cooper C, Milne F. Are most maternal deaths from pre-eclampsia avoidable? Lancet. 2012 May 5;379(9827):1686-7. doi: 10.1016/S0140-6736(11)60785-X. Epub 2011 Dec 14. No abstract available. — View Citation

Tun C, Quinones JN, Kurt A, Smulian JC, Rochon M. Comparison of 12-hour urine protein and protein:creatinine ratio with 24-hour urine protein for the diagnosis of preeclampsia. Am J Obstet Gynecol. 2012 Sep;207(3):233.e1-8. doi: 10.1016/j.ajog.2012.06.010. Epub 2012 Jun 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary to validate a shorter urine collection time for assessment of proteinuria urine collection over 6 and 12 hours to compare with results of the official 24 hours urine collection for proteinuria in the investigation of suspected preeclampsia one year
Primary To examine if a shorter urine collection time for assessment of proteinuria is comparable to the standard 24 hours one year
See also
  Status Clinical Trial Phase
Completed NCT03510286 - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Recruiting NCT03313024 - Berlin-Brandenburg Pregnancy Cohort
Active, not recruiting NCT04990141 - Molecular Screening Method for Preeclampsia (PREMOM)
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT05999851 - Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy N/A
Recruiting NCT02923206 - Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis N/A
Terminated NCT02558023 - The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine Phase 3
Not yet recruiting NCT02541110 - Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler N/A
Completed NCT02854501 - Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
Completed NCT02384226 - User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
Withdrawn NCT05016440 - Lisinopril for Renal Protection in Postpartum Preeclamptic Women N/A
Completed NCT02554604 - Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
Recruiting NCT02337049 - Preeclampsia Subtypes and Surrogate Markers of CVD Risk N/A
Recruiting NCT02247297 - Pancreatic Stone Protein (PSP) in Pregnant Women
Completed NCT02238704 - Cornell University-Micronutrient Initiative Calcium Supplementation Study N/A
Completed NCT01195441 - Prediction and Prevention of Preeclampsia by First Trimester Ultrasound N/A
Withdrawn NCT01179542 - The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR N/A
Completed NCT00456118 - Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
Recruiting NCT00117546 - Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia Phase 4
Completed NCT00787241 - Platelet Count Trends in Pre-eclamptic Parturients N/A